Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 5 · 62.5%High 1 · 12.5%

JAK inhibitors plus standard of care vs placebo or usual care

Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 10802 participants
Moderate

JAK inhibitors plus standard of care vs placebo or usual care

OutcomesTime frame of absolute effects · hospitalised people with confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

JAK inhibitors plus standard of care vs placebo or usual care

All‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 11145 participants
Moderate

JAK inhibitors plus standard of care vs placebo or usual care

All‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1626 participants
High

JAK inhibitors plus standard of care vs placebo or usual care

Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 9417 participants
Moderate

JAK inhibitors plus standard of care vs placebo or usual care

Adverse events: all grades · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1885 participants
Moderate

JAK inhibitors plus standard of care vs placebo or usual care

Serious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2901 participants
Moderate

JAK inhibitors plus standard of care vs placebo or usual care

Secondary infection · hospitalised people with confirmed SARS‐CoV‐2 infection

1 finding from 1 review

Janus kinase inhibitors for the treatment of COVID‐19 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 10041 participants
Low